Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

CIBC World Keeps 'Strong Buy' on Andrx

CIBC World reiterates strong buy on Andrx (ADRX).

Analyst Elliot Wilbur says AstraZeneca's news is positive for Andrx, as it removes a hurdle in Andrx's attempts to market a generic version of the ulcer and heartburn drug Prilosec. He notes AstraZeneca indicated that under a non-exclusive license pact with aaiPharma, it does not plan to list U.S. patents 6,262,085 & 6,262,086. Wilbur continues to believe Andrx is the best new product story in his specialty pharmaceutical universe. He has a $125 target, but notes price appreciation near-term remains captive to ongoing Prilosec developments.

blog comments powered by Disqus